Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders - Institut Pasteur Access content directly
Journal Articles The Journal of Allergy and Clinical Immunology: In Practice Year : 2022

Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders

David Launay
  • Function : Author
Richard Lemal
  • Function : Author
Celine Greco
  • Function : Author
Laurent Frenzel
  • Function : Author
Cecile Meni
  • Function : Author
Christine Bodemere-Skandalis
  • Function : Author
Laura Polivka
  • Function : Author
Anne-Florence Collange
  • Function : Author
Hassiba Hachichi
  • Function : Author
Sonia Bouzourine
  • Function : Author
Djazira Nait Messaoud
  • Function : Author
Mathilde Negretto
  • Function : Author
Laurence Vendrame
  • Function : Author
Marguerite Jambou
  • Function : Author
Marie Gousseff
  • Function : Author
Stéphane Durupt
  • Function : Author
Jean-Christophe Lega
  • Function : Author
Jean-Marc Durand
  • Function : Author
Caroline Gaudy
  • Function : Author
Gandhi Damaj
  • Function : Author
Marie-Pierre Gourin
  • Function : Author
Mohamed Hamidou
  • Function : Author
Laurence Bouillet
  • Function : Author
Edwige Le Mouel
  • Function : Author
Alexandre Maria
  • Function : Author
Patricia Zunic
  • Function : Author
Quentin Cabrera
  • Function : Author
Denis Vincent
  • Function : Author
Christian Lavigne
  • Function : Author
Etienne Riviere
  • Function : Author
Clement Gourguechon
  • Function : Author
Marie Courbebaisse
  • Function : Author
David Lebeaux
  • Function : Author
Béatrice Parfait
  • Function : Author
Gérard Friedlander
  • Function : Author
Anne Brignier
  • Function : Author
Ludovic Lhermitte
  • Function : Author
Thierry Jo Molina
  • Function : Author
Julie Bruneau
  • Function : Author
Julie Agopian
  • Function : Author
Dana Ranta
  • Function : Author
Alexandre Mania
  • Function : Author
Michel Arock
  • Function : Author
Isabelle Staropoli
Olivier Schwartz

Abstract

Background Mast cells are key players in innate immunity and the TH2 adaptive immune response. The latter counterbalances the TH1 response, which is critical for antiviral immunity. Clonal mast cell activation disorders (cMCADs, such as mastocytosis and clonal mast cell activation syndrome) are characterized by abnormal mast cell accumulation and/or activation. No data on the antiviral immune response in patients with MCADs have been published. Objective To study a comprehensive range of outcomes in patients with cMCAD with PCR- or serologically confirmed coronavirus disease 2019 and to characterize the specific anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune response in this setting. Methods Clinical follow-up and outcome data were collected prospectively over a 12-month period by members of the French Centre de Référence des Mastocytoses rare disease network. Anti–SARS-CoV-2–specific T-cell activity was measured with an ELISA, and humoral responses were evaluated by assaying circulating levels of specific IgG, IgA, and neutralizing antibodies. Results Overall, 32 patients with cMCAD were evaluated. None required noninvasive or mechanical ventilation. Two patients were admitted to hospital for oxygen and steroid therapy. The SARS-CoV-2–specific immune response was characterized in 21 of the 32 patients. Most had high counts of circulating SARS-CoV-2–specific, IFN-γ–producing T cells and high titers of neutralizing antispike IgGs. The patients frequently showed spontaneous T-cell IFN-γ production in the absence of stimulation; this production was correlated with basal circulating tryptase levels (a marker of the mast cell burden). Conclusions Patients with cMCADs might not be at risk of severe coronavirus disease 2019, perhaps due to their spontaneous production of IFN-γ.

Dates and versions

pasteur-03697054 , version 1 (16-06-2022)

Identifiers

Cite

Julien Rossignol, Amani Ouedrani, Cristina Bulai Livideanu, Stéphane Barete, Louis Terriou, et al.. Effective Anti–SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders. The Journal of Allergy and Clinical Immunology: In Practice, 2022, 10 (5), pp.1356-1364.e2. ⟨10.1016/j.jaip.2021.12.038⟩. ⟨pasteur-03697054⟩
53 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More